Founded in 2000
Financial data: €1.11B Market Cap (on 26/11/2015)
Basilea develops and commercializes innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology.
Deals & Finance
Monster €167M NASDAQ-IPO coming for Swiss Antibiotic Biotech Basilea
Rise of the Superbugs: How is Biotech Fighting Antibiotic Resistance?
From The Bench
Parent Bacteria Resist Antibiotics Better than their Offspring
The Top 12 Biotech Leaders you should know in Basel
Labiotech UG, All Rights Reserved -
Send this to friend